Inventor · disambiguated record
Guochun Gong
Also filed as: GONG GUOCHUN
16 granted patents·13 pending applications·89 citations·filing 2010–2024
91Inventor score
Top patents by PatentIndex Score
29 records- 0196US8518392B2Promoter-regulated differentiation-dependent self-deleting cassetteFRENDEWEY DAVID·Filed 2010·Granted Aug 27, 2013·57 cites·11 claims
- 0294US8946505B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2013·Granted Feb 3, 2015·10 cites·11 claims
- 0394US8946504B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2013·Granted Feb 3, 2015·10 cites·16 claims
- 0489US9410163B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2014·Granted Aug 9, 2016·3 cites·12 claims
- 0587US11519004B2Transcription modulation in animals using CRISPR/Cas systemsREGENERON PHARMA·Filed 2019·Granted Dec 6, 2022·4 cites·35 claims
- 0680US11130999B2Cas-ready mouse embryonic stem cells and mice and uses thereofREGENERON PHARMA·Filed 2018·Granted Sep 28, 2021·1 cites·36 claims
- 0780US10548302B2Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophyREGENERON PHARMA·Filed 2017·Granted Feb 4, 2020·1 cites·30 claims
- 0879US11021719B2Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2018·Granted Jun 1, 2021·1 cites·30 claims
- 0978US2024093316A1Cas-ready mouse embryonic stem cells and mice and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1076US2023189771A1Lincrna-deficient non-human animalsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1175US2024301442A1Methods and compositions for insertion of antibody coding sequences into a safe harbor locusREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1274US10285388B2Non-human animals having a disruption in a C9ORF72 locusREGENERON PHARMA·Filed 2016·Granted May 14, 2019·2 cites·30 claims
- 1373US11866794B2Cas-ready mouse embryonic stem cells and mice and uses thereofREGENERON PHARMA·Filed 2021·Granted Jan 9, 2024·0 cites·18 claims
- 1471US9554564B2IncRNA-knockout miceREGENERON PHARMA·Filed 2014·Granted Jan 31, 2017·0 cites·29 claims
- 1571US2014199761A1Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 1669US9677086B2Promoter-regulated differentiation-dependent self-deleting cassetteREGENERON PHARMA·Filed 2016·Granted Jun 13, 2017·0 cites·20 claims
- 1768US11730150B2Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophyREGENERON PHARMA·Filed 2019·Granted Aug 22, 2023·0 cites·20 claims
- 1864US11547101B2Non-human animals having a disruption in a C9ORF72 locusREGENERON PHARMA·Filed 2019·Granted Jan 10, 2023·0 cites·8 claims
- 1963US2021261985A1Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2062US2025332287A1Identification of tissue-specific extragenic safe harbors for gene therapy approachesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2161US11547100B2Method for screening gene expression in lincRNA-deficient mice or ratsREGENERON PHARMA·Filed 2016·Granted Jan 10, 2023·0 cites·8 claims
- 2258US10196613B2Stem cells for modeling type 2 diabetesREGENERON PHARMA·Filed 2015·Granted Feb 5, 2019·0 cites·12 claims
- 2358US2020318136A1Methods and compositions for insertion of antibody coding sequences into a safe harbor locusREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2458US2019136201A1Stem cells for modeling type 2 diabetesREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 2554US2021079394A1Transcription modulation in animals using crispr/cas systems delivered by lipid nanoparticlesREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2653US2014221734A1Cloned non-human animals free of selective markersREGENERON PHARMA·Filed 2013·Application pending·0 cites
- 2751US2019032156A1Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivoREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 2848US2014075586A1Parental Cell Lines for Making Cassette-Free F1 ProgenyREGENERON PHARMA·Filed 2013·Application pending·0 cites
- 2948US2023102342A1Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of useREGENERON PHARMA·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Guochun Gong files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →